200 related articles for article (PubMed ID: 12915464)
21. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
22. The interleukin 23 receptor gene in multiple sclerosis: a case-control study.
Roos IM; Kockum I; Hillert J
J Neuroimmunol; 2008 Feb; 194(1-2):173-80. PubMed ID: 18164077
[TBL] [Abstract][Full Text] [Related]
23. Exploiting genotypic differences to identify genes important for EAE development.
Jelinsky SA; Miyashiro JS; Saraf KA; Tunkey C; Reddy P; Newcombe J; Oestreicher JL; Brown E; Trepicchio WL; Leonard JP; Marusic S
J Neurol Sci; 2005 Dec; 239(1):81-93. PubMed ID: 16214174
[TBL] [Abstract][Full Text] [Related]
24. Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke.
Lampe JW; Stepaniants SB; Mao M; Radich JP; Dai H; Linsley PS; Friend SH; Potter JD
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):445-53. PubMed ID: 15006922
[TBL] [Abstract][Full Text] [Related]
25. Effects of sex hormones on costimulatory molecule expression in multiple sclerosis.
Pelfrey CM; Moldovan IR; Cotleur AC; Zamor N; Rudick RA
J Neuroimmunol; 2005 Oct; 167(1-2):190-203. PubMed ID: 16046001
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.
Couturier N; Bucciarelli F; Nurtdinov RN; Debouverie M; Lebrun-Frenay C; Defer G; Moreau T; Confavreux C; Vukusic S; Cournu-Rebeix I; Goertsches RH; Zettl UK; Comabella M; Montalban X; Rieckmann P; Weber F; Müller-Myhsok B; Edan G; Fontaine B; Mars LT; Saoudi A; Oksenberg JR; Clanet M; Liblau RS; Brassat D
Brain; 2011 Mar; 134(Pt 3):693-703. PubMed ID: 21354972
[TBL] [Abstract][Full Text] [Related]
27. Characterization of Multiple Sclerosis candidate gene expression kinetics in rat experimental autoimmune encephalomyelitis.
Thessen Hedreul M; Gillett A; Olsson T; Jagodic M; Harris RA
J Neuroimmunol; 2009 May; 210(1-2):30-9. PubMed ID: 19269041
[TBL] [Abstract][Full Text] [Related]
28. The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis.
Thangarajh M; Kisiswa L; Pirskanen R; Hillert J
Scand J Immunol; 2007 May; 65(5):461-6. PubMed ID: 17444957
[TBL] [Abstract][Full Text] [Related]
29. [Molecular biomarkers for prediction of multiple sclerosis relapse].
Satoh J
Nihon Rinsho; 2008 Jun; 66(6):1103-11. PubMed ID: 18540355
[TBL] [Abstract][Full Text] [Related]
30. Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression.
Kantarci OH; Hebrink DD; Schaefer-Klein J; Sun Y; Achenbach S; Atkinson EJ; Heggarty S; Cotleur AC; de Andrade M; Vandenbroeck K; Pelfrey CM; Weinshenker BG
Arch Neurol; 2008 Mar; 65(3):349-57. PubMed ID: 18332247
[TBL] [Abstract][Full Text] [Related]
31. Analyses of immunosenescent markers in patients with autoimmune disease.
Thewissen M; Somers V; Venken K; Linsen L; van Paassen P; Geusens P; Damoiseaux J; Stinissen P
Clin Immunol; 2007 May; 123(2):209-18. PubMed ID: 17317320
[TBL] [Abstract][Full Text] [Related]
32. Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis.
Galimberti D; Scalabrini D; Fenoglio C; De Riz M; Comi C; Venturelli E; Cortini F; Piola M; Leone M; Dianzani U; D'Alfonso S; Monaco F; Bresolin N; Scarpini E
J Neurol Sci; 2008 Apr; 267(1-2):86-90. PubMed ID: 17967467
[TBL] [Abstract][Full Text] [Related]
33. A subtype of multiple sclerosis defined by an activated immune defense program.
van Baarsen LG; van der Pouw Kraan TC; Kragt JJ; Baggen JM; Rustenburg F; Hooper T; Meilof JF; Fero MJ; Dijkstra CD; Polman CH; Verweij CL
Genes Immun; 2006 Sep; 7(6):522-31. PubMed ID: 16837931
[TBL] [Abstract][Full Text] [Related]
34. Genomic regulation of CTLA4 and multiple sclerosis.
Palacios R; Comas D; Elorza J; Villoslada P
J Neuroimmunol; 2008 Oct; 203(1):108-15. PubMed ID: 18691768
[TBL] [Abstract][Full Text] [Related]
35. T lymphocyte activation gene identification by coregulated expression on DNA microarrays.
Mao M; Biery MC; Kobayashi SV; Ward T; Schimmack G; Burchard J; Schelter JM; Dai H; He YD; Linsley PS
Genomics; 2004 Jun; 83(6):989-99. PubMed ID: 15177553
[TBL] [Abstract][Full Text] [Related]
36. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
37. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells.
Iglesias AH; Camelo S; Hwang D; Villanueva R; Stephanopoulos G; Dangond F
J Neuroimmunol; 2004 May; 150(1-2):163-77. PubMed ID: 15081262
[TBL] [Abstract][Full Text] [Related]
38. FcRL3 and multiple sclerosis pathogenesis: role in autoimmunity?
Martínez A; Mas A; de Las Heras V; Bartolomé M; Arroyo R; Fernández-Arquero M; de la Concha EG; Urcelay E
J Neuroimmunol; 2007 Sep; 189(1-2):132-6. PubMed ID: 17617473
[TBL] [Abstract][Full Text] [Related]
39. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis.
Kantarci OH; Morales Y; Ziemer PA; Hebrink DD; Mahad DJ; Atkinson EJ; Achenbach SJ; De Andrade M; Mack M; Ransohoff RM; Lassmann H; Bruck W; Weinshenker BG; Lucchinetti CF
J Neuroimmunol; 2005 Dec; 169(1-2):137-43. PubMed ID: 16182378
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression.
Pigard N; Elovaara I; Kuusisto H; Paalavuo R; Dastidar P; Zimmermann K; Schwarz HP; Reipert B
J Neuroimmunol; 2009 Apr; 209(1-2):114-20. PubMed ID: 19217671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
